Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 9/20 | 0.38 |
| ▸ | CNR2 | P34972 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24437121 | 0.80 | CHRM1 (0.39) | MAPTCNR1CNR2 | |
| SCHEMBL24437303 | 0.77 | CNR1 (0.56) | L3MBTL1HTTCNR1CNR2ALDH1A1 | |
| SCHEMBL24437378 | 0.76 | CNR1 (0.60) | L3MBTL1MAPTCNR1CNR2ALDH1A1 | |
| SCHEMBL24437306 | 0.71 | CNR1 (0.52) | MAPTHTTCNR1CNR2ALDH1A1 | |
| SCHEMBL24437193 | 0.70 | CNR1 (0.55) | HTTCNR1CNR2ALDH1A1 | |
| SCHEMBL24437316 | 0.68 | CNR1 (0.53) | PDE4ACNR1CNR2ALDH1A1MEN1 | |
| SCHEMBL24437138 | 0.67 | CNR1 (0.57) | PDE4ACNR1CNR2ALDH1A1 | |
| SCHEMBL24437167 | 0.66 | NPC1 (0.42) | DHODHMAPTALDH1A1KMT2A | |
| SCHEMBL7454630 | 0.64 | L3MBTL1 (0.43) | L3MBTL1PDE4AMAPTHTTLMNA | |
| SCHEMBL24437256 | 0.63 | CNR1 (0.52) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | ORAI2, ORAI1, ORAI3 | FABP3 2924/4885L3MBTL1 4680/4885PDE4A 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.